Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
45.85
-1.60 (-3.37%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 830.44 | 718.95 | 661.82 | 607.52 | 667.24 | 579.78 | |
Revenue Growth | 24.85% | 8.63% | 8.94% | -8.95% | 15.09% | 11.41% |
Cost of Revenue | 225.13 | 180.8 | 186.7 | 175.37 | 87.22 | 75.06 |
Gross Profit | 605.31 | 538.16 | 475.12 | 432.15 | 580.02 | 504.71 |
Selling, General & Admin | 496.75 | 422.94 | 335.78 | 336.36 | 377.22 | 304.76 |
Research & Development | - | - | - | - | 74.55 | 90.47 |
Amortization of Goodwill & Intangibles | 99.83 | 89.46 | 77.98 | 82.39 | 82.63 | 29.99 |
Operating Expenses | 596.58 | 512.39 | 413.76 | 418.75 | 534.4 | 425.22 |
Operating Income | 8.73 | 25.76 | 61.36 | 13.4 | 45.61 | 79.5 |
Interest Expense | -2.32 | - | - | -2.42 | -7.07 | -23.42 |
Interest & Investment Income | 9.75 | 13.69 | 16.2 | 10.45 | - | 10.22 |
Other Non Operating Income (Expenses) | - | - | - | - | 21.68 | - |
EBT Excluding Unusual Items | 16.17 | 39.45 | 77.55 | 21.44 | 60.22 | 66.3 |
Merger & Restructuring Charges | -72.93 | -72.93 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.44 | -0.44 | 0.01 | - | 0.01 | 0.35 |
Asset Writedown | -54.92 | - | - | -20.19 | - | - |
Other Unusual Items | -20.15 | -25.42 | 6.11 | 1.52 | 0.51 | 6.53 |
Pretax Income | -123.47 | -49.03 | 97.87 | 2.77 | 60.74 | 73.18 |
Income Tax Expense | -13.58 | -10.48 | 24.01 | 1.45 | 0.03 | 19.75 |
Net Income | -109.89 | -38.55 | 73.87 | 1.32 | 60.71 | 53.42 |
Net Income to Common | -109.89 | -38.55 | 73.87 | 1.32 | 60.71 | 53.42 |
Net Income Growth | - | - | 5512.84% | -97.83% | 13.64% | -57.92% |
Shares Outstanding (Basic) | 57 | 56 | 55 | 55 | 54 | 53 |
Shares Outstanding (Diluted) | 57 | 56 | 56 | 56 | 62 | 54 |
Shares Change | 1.67% | 0.88% | 0.81% | -10.01% | 13.47% | 1.24% |
EPS (Basic) | -1.91 | -0.68 | 1.34 | 0.02 | 1.13 | 1.01 |
EPS (Diluted) | -1.91 | -0.68 | 1.32 | 0.02 | 1.04 | 0.98 |
EPS Growth | - | - | 6500.00% | -98.08% | 6.32% | -58.48% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 18.79 | 45.99 | 171.23 | 110.53 | 116.41 | 125.08 |
Free Cash Flow Per Share | 0.33 | 0.81 | 3.06 | 1.99 | 1.89 | 2.30 |
Gross Margin | 72.89% | 74.85% | 71.79% | 71.13% | 86.93% | 87.05% |
Operating Margin | 1.05% | 3.58% | 9.27% | 2.21% | 6.84% | 13.71% |
Profit Margin | -13.23% | -5.36% | 11.16% | 0.22% | 9.10% | 9.21% |
Free Cash Flow Margin | 2.26% | 6.40% | 25.87% | 18.19% | 17.45% | 21.57% |
EBITDA | 110.43 | 117.32 | 141.77 | 98.26 | 131.16 | 112.09 |
EBITDA Margin | 13.30% | 16.32% | 21.42% | 16.17% | 19.66% | 19.33% |
D&A For EBITDA | 101.7 | 91.56 | 80.41 | 84.86 | 85.54 | 32.6 |
EBIT | 8.73 | 25.76 | 61.36 | 13.4 | 45.61 | 79.5 |
EBIT Margin | 1.05% | 3.58% | 9.27% | 2.21% | 6.84% | 13.71% |
Effective Tax Rate | - | - | 24.53% | 52.47% | 0.05% | 26.99% |
Revenue as Reported | 830.44 | 718.95 | 661.82 | 607.52 | 667.24 | 579.78 |